Introduction {#sec1-1}
============

Endothelial cells regulate vascular tone by releasing various relaxing and contracting factors including nitric oxide (NO), endothelium-derived hyperpolarizing factors, arachidonic acid metabolites, reactive oxygen species (ROS), and other vasoactive peptides. \[[@ref1]\] Obviously, the mechanisms of endothelium-dependent responses are complex, and the modulation by age and disease leads to endothelial dysfunction, which has become a predictor of major cardiovascular diseases. \[[@ref2]\] Endothelium-dependent relaxation (EDR) impairment is usually the initial event of endothelial dysfunction. Though the etiology of EDR impairment is multi-factorial and not fully elucidated, overproduction of ROS under pathophysiologic conditions, alterations of endothelial nitric oxide synthase (eNOS) expression and activity, and decreased bioavailability of NO have all been considered responsible for the impairment of EDR. \[[@ref3][@ref4]\]

The physiological NO in the vasculature is mainly produced by eNOS, \[[@ref5]\] and interruption of endothelial-derived NO elevates arterial blood pressure accompanied with impaired vascular responses to acetylcholine (ACh). \[[@ref6][@ref7]\] Overproduction of superoxide anion (O~2~^-^) induced by diabetes, hypercholesterolemia, and other diseases quickly scavenges the bioactivity of NO by generating peroxynitrite (ONOO^-^), a potent cytotoxic ROS. \[[@ref8]\] Furthermore, ONOO^-^ itself causes uncoupling of nitric oxide synthase (NOS) to produce superoxide instead of NO, \[[@ref9]\] which exacerbates the oxidative stress and impairment of EDR leading to endothelial dysfunction. \[[@ref10]\] So it is suggested that steps improving endothelial-derived NO bioavailability in oxidative stress may have potential protection against endothelial dysfunction.

*Zizyphi Spinosi* semen (ZSS), a traditional Chinese herb for treating neurasthenia, \[[@ref11]\] is the dried seed of *Zizyphus jujuba* var. spinosa, and has been demonstrated being beneficial to the cardiovascular system by modern pharmacological studies, such as reducing myocardial ischemia injury and enhancing endothelium-derived NO bioavailability. \[[@ref12][@ref13]\] Betulinic acid (BA), the key active constituent of ZSS, may mediate such cardiovascular effects through upregulation of eNOS and downregulation of NADPH oxidase. \[[@ref13]\] Recently, BA was reported to reduce cerebral ischemia-reperfusion injury in mice by decreasing oxidative stress and nitrosative stress, as well enhancing blood flow. \[[@ref14]\] We thereby hypothesized that BA may attenuate the impairment of EDR induced by exogenous oxidants via modulating the bioavailability of endothelium derived NO.

Therefore, the aim of this work was to explore the effect of BA on ACh-induced EDR in rat thoracic aortas exposed to pyrogallol-produced O~2~^-^. To clarify the underlying mechanism, NO level, ROS production, activity of NOS, and superoxide dismutase (SOD) in aortas were measured.

Materials and Methods {#sec1-2}
=====================

 {#sec2-1}

### Animals {#sec3-1}

Male Sprague-Dawley rats (4--6 months old and weighing 240-270 g) were obtained from the Experimental Animal Center of Zhejiang Academy of Medical Sciences. All procedures were performed according to the protocols approved by the Institutional Committee for Use and Care of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996). The experiments were approved by the Ethics Committee for the Use of Experimental Animals in Jiaxing University.

### Drugs and Chemicals {#sec3-2}

BA was obtained from Shanghai Tauto Biotech Co., Ltd. (Shanghai, China), and the purity was 98% by high performance liquid chromatography (HPLC). ACh, phenylephrine (PE), N^w^ -nitro-l-arginine methyl ester hydrochloride (L-NAME), methylene blue (MB), and indomethacin (Indo) were from Sigma-Aldrich Inc. (Saint Louis, MO, USA). 3-amino,4- aminomethyl-2',7'-difluorescein, diacetate (DAF-FM DA) and 2',7'-dichlorfluorescin- diacetate (DCFH-DA) were from Molecular Probes (Eugene, OR, USA). The kits for measurement of NOS and SOD were from Nanjing Jiancheng Bioengineering Institute (Nanjing, China). All other reagents were of analytical purity.

### Preparation of Rat Thoracic Aortic Rings and Bioassay of Vasoreactivity {#sec3-3}

Bioassay of vasoreactivity in the organ bath system was based on the methods of Qian *et al*. with modifications. \[[@ref15]\] Briefly, rats were anesthetized with chloral hydrate (400 mg/kg, *i.p*.) and killed by cervical dislocation. The descending thoracic aorta was rapidly dissected out, cut approximately 4 mm in length, and mounted in a 10 ml organ bath containing Krebs' solution at 37°C bubbled with 95% O~2~ + 5% CO~2~ (pH 7.4), composed of (mM): NaCl 118; KCl 4.7; KH~2~ PO~4~ 1.2; MgSO~4~ 1.2; NaHCO~3~ 25; glucose 10; and CaCl~2~ 2.5. Before each experiment, aortic rings were stimulated three times with 60 mM KCl until a reproducible contractile response was obtained. The presence of functional endothelium was verified by the ability of ACh (10 μM) to induce more than 80% relaxation of aortic rings previously contracted by PE (1 μM).

### Aortic Endothelial Impairment in Pyrogallol-Produced O~2~ -- {#sec3-4}

As in the previous studies, \[[@ref16][@ref17]\] an arterial injury by O~2~^-^ was accomplished through the auto-oxidation of pyrogallol added to the organ baths. After 15 min incubation in pyrogallol (500 μM), the cumulative concentration-response curves to ACh (10^-9^--l0^-5^M) were generated in rings previously contracted by PE (1 μM) in fresh Krebs' solution.

### Assay of NOS and SOD Activity {#sec3-5}

As in the previous studies, \[[@ref18]\] aortic SOD activity was assayed by the xanthine--xanthine oxidase method, and total NOS (tNOS) (constitutive NOS \[cNOS\] + inducible NOS \[iNOS\]) and iNOS activity were assayed following the kit manual. The tNOS activity minus the iNOS activity gave the cNOS activity (in rat aortas the main cNOS is eNOS).

### Measurement of ROS Release and NO Release {#sec3-6}

Determination of NO and ROS was based on the methods of previous studies with modifications. \[[@ref19]\] After the supernatant was obtained from the aortic homogenate, it was pipetted into 96-well black plates (49.5 μl/well) loaded with 10 μM DCFH-DA or 10 μM DAF-FM DA for 30 min at room temperature in the dark. Levels of DCF in the supernatant were measured by microplate reader using 488 nm excitation and 530 nm emission. Levels of DAF-FM in the supernatant were measured by microplate reader using 495 nm excitation and 515 nm emission. Background fluorescence was corrected by the inclusion of parallel blanks. ROS or NO production was expressed as percentage compared with the control group.

### Protocols of Experiments {#sec3-7}

The first series of experiments were designed to evaluate the effect of BA on EDR. PE (1 μM) was used to induce steady contraction in endothelium-intact aortic rings, then BA (0.1--100 μM) was added cumulatively. The half-maximum effective concentration (EC~50~), which was defined as the concentration of BA that induced 50% of maximum relaxation from the contraction elicited by PE, was calculated.

The second series of experiments were designed to evaluate protective effects of BA against the ACh-induced EDR of aortic rings exposed to pyrogallol-produced O~2~^-^. Experiments were carried out in six groups with eight endothelium-intact aortic rings from eight rats in each group: (1) Control group (Con), endothelium-intact rings incubated in Krebs' solution; (2) BA alone (BA), endothelium-intact rings preincubated with BA at the EC~50~ for 30 min; (3) Pyrogallol, rings preincubated with 500 μM pyrogallol for 15 min; (4) BA+pyrogallol, endothelium-intact rings incubated with BA at the EC~50~ for 30 min, and 500 μM pyrogallol for the last 15 min; (5) L-NAME+BA+pyrogallol, rings preincubated with 100 μM L-NAME for 30 min before incubating with BA at the EC~50~ for another 30 min, and 500 μM pyrogallol for the last 15 min; (6) Indo+BA+pyrogallol, rings preincubated with 10 μM Indo for 30 min before incubating with BA at the EC~50~ for another 30 min, and 500 μM pyrogallol for the last 15 min; (7) MB+BA+pyrogallol, rings preincubated with 10 μM MB before incubating with BA at the EC~50~ for another 30 min, and 500 μM pyrogallol for the last 15 min. L-NAME, Indo, and MB were washed prior to the incubation of BA. After completion of these treatments, the rings were incubated in normal Krebs' solution and ACh-induced EDR was performed.

### Statistical Analysis {#sec3-8}

All data are expressed as mean ± SD. The BA/ACh-induced maximal relaxation (E~max~) in aortic rings was calculated as a percentage of the contraction elicited by PE (1 μM). The half-maximum effective concentration (EC~50~) was defined as the concentration of BA or ACh that induced 50% of maximum vasorelaxation of the contraction elicited by PE, which was calculated from the concentration-response curve by nonlinear regression (curve fit) using GraphPad Prism 5.0 (GraphPad Software Inc., San Diego, CA, USA), and pD~2~ is the negative logarithm of the EC~50~. Statistical comparisons were made using the one-way analysis of variance (ANOVA) followed by the Newman--Keuls test. A value of *P* \< 0.05 was considered statistically significant.

Results {#sec1-3}
=======
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### Effect of BA on Relaxation in Aortas Previously Contracted by PE {#sec3-9}

In the endothelium-intact aortic rings previously contracted by PE, BA (0.1--100 μM) evoked a concentration-dependent EDR \[[Figure 1](#F1){ref-type="fig"}\], the E~max~ reached 79.06 ± 12.18%, and the pD~2~ was 5.80 ± 0.10, EC~50~ was 1.58 μM. We chose the approximate value of EC~50~ (2.0 μM) as the experimental concentration of BA for subsequent experiments.

![Effect of betulinic acid (BA, 0.1--100 μM) on vasorelaxation of endothelium-intact (+E) and -denuded (-E) aortic rings p reviously contracted by 1 μM phenylephrine (PE). Tension was measured and calculated as a percentage of the contraction elicited by PE. All data are expressed as mean ± SD; n = 7 rings from the seven rats per group. \*\**P* \< 0.01 vs. Con](IJPharm-44-588-g001){#F1}

In the endothelium-denuded aortic rings previously contracted by PE, BA (0.1--100 μM) did not evoke obvious vasorelaxation, the E~max~ reached 13.99 ± 8.29% \[*P* \> 0.05 vs. the endothelium-denuded control group, [Figure 1](#F1){ref-type="fig"}\].

### Effect of BA on ACh-Induced EDR in Aortas Preincubated with Pyrogallol and Previously Contracted by PE {#sec3-10}

The ACh-induced EDR in the aortic rings exposed to pyrogallol was significantly impaired, and the E~max~ decreased to 23.91 ± 5.41% \[*P* \< 0.01 vs. Con, [Figure 2a](#F2){ref-type="fig"}\]. However, pretreatment with BA attenuated the dysfunction of relaxation induced by exposure to pyrogallol, and the E~max~ increased to 42.45 ± 9.99% \[*P* \< 0.01 vs. pyrogallol, [Figure 2a](#F2){ref-type="fig"}\], which was markedly reversed by both L-NAME, the inhibitor of NOS, and MB, a guanylyl cyclase inhibitor, but not by pretreatment with Indo, a cyclooxygenase inhibitor [Figure 2b](#F2){ref-type="fig"}\]. Without exposure to pyrogallol, preincubation with BA also enhanced the ACh-induced relaxation, the E~max~ increased to 74.61 ± 4.75% in BA group \[*P* \< 0.05 vs. Con, [Figure 2a](#F2){ref-type="fig"}\].

![Effect of betulinic acid (BA, 2.0 μM) on acetylcholine (ACh)-induced vasorelaxation in endothelium-intact rat aortic rings previously contracted by 1 μM phenylephrine (PE) after exposure to pyro gallol (500 μM) for 15 min. Tension was measured and calculated as a percentage of the contraction in response to PE. Con: rings without any pretreatments; BA: rings preincubated with BA for 30 min; Pyrogallol: rings preincubated with pyrogallol for 15 min; BA+pyrogallol: rings incubated with BA for 30 min, and pyrogallol for the last 15 min; L-NAME/Indo/MB+BA+pyrogallol: rings preincubated with L-NAME (100 μM), indomethacin (Indo, 10 μM), or methylene blue (MB, 10 μM) for 30 min and then washed before incubating with BA for another 30 min, and pyrogallol for the last 15 min. All data are expressed as mean ± SD; n = 8 rings from the eight rats per group. ^\*^*P* \< 0.05, ^\*\*^*P* \< 0.01 vs. Con; \#\#*P* \< 0.01 vs. pyrogallol; +*P* \< 0.05, ++*P* \< 0.01 vs. BA+pyrogallol](IJPharm-44-588-g002){#F2}

### Effect of BA on ROS Level and SOD Activity in Aortas Preincubated with Pyrogallol {#sec3-11}

As shown in [Figure 3a](#F3){ref-type="fig"}, we found that ROS level was markedly increased to 242.99% in aortas exposed to pyrogallol (*P* \< 0.01 vs. Con), which was attenuated by treatment with BA (*P* \< 0.01 vs. pyrogallol). The decrease of aortic SOD activity induced by pyrogallol was significantly reversed by BA \[*P* \< 0.01 vs. pyrogallol, [Figure 3b](#F3){ref-type="fig"}\]. Treatment with BA alone had no significant effect on ROS level and SOD activity.

![Effect of betulinic acid (BA, 2.0 μM) on ROS level (a) and activity of SOD (b) in endothelium-intact rat aortas exposed to pyrogallol (500 μM) for 15 min. All data are expressed as mean ± SD; *n* = 8 aortas fro m the eight rats per group. ^\*\*^*P* \< 0.01 vs. Con; \#\#*P* \< 0.01 vs. pyrogallol](IJPharm-44-588-g003){#F3}

### Effect of BA on NO Level and NOS Activity in Aortas Preincubated with Pyrogallol {#sec3-12}

The decrease of NO level in aortas exposed to pyrogallol was markedly inhibited by BA \[*P* \< 0.01 vs. pyrogallol, [Figure 4a](#F4){ref-type="fig"}\]. As shown in [Figure 4b](#F4){ref-type="fig"}, BA also inhibited the decrease of cNOS activity in aortas induced by pyrogallol (*P* \< 0.01 vs. pyrogallol). Treatment with BA alone markedly increased NO level and cNOS activity in normal rat aortas.

![Effect of betulinic acid (BA, 2.0 μM) on NO level (a) and activity of constitutive nitric oxide synthase (cNOS) (b) in aortas exposed to pyrogallol (500 μM) for 15 min. All data are expressed as mean ± SD; *n* = 8 aortas from the eight rats per group. ^\*\*^*P* \< 0.01 vs. Con; \#\#*P* \< 0.01 vs. pyrogallol](IJPharm-44-588-g004){#F4}

Discussion {#sec1-4}
==========

Our current work shows that BA(0.1--100 μM) evoked a concentration-dependent EDR in aortic rings, and demonstrates for the first time that BA improved EDR in aortas exposed to pyrogallol. Moreover, exposure to pyrogallol exacerbated ROS production, weakened NO level and the activities of SOD and cNOS in aorta, all of which were reversed by pretreatment with BA.

NO and prostacyclin (PGI~2~) are two relaxing factors to modulate EDR in the rat thoracic aorta. \[[@ref20]\] NO is mainly formed in the endothelium by the activation of eNOS and diffuses out of the endothelial cell to vascular smooth muscle cells where it activates soluble guanylyl cyclase (sGC) to produce cyclic guanosine monophosphate (cGMP). The rise of cGMP initiates the relaxation of the vascular smooth muscle. \[[@ref21]\] Here, we found that the improvement of EDR exerted by BA in aortas subjected to pyrogallol derived O~2~^-^ was reversed by the NOS inhibitor L-NAME and sGC inhibitor MB, but not by Indo, the inhibitor of cyclooxygenase (the rate-limiting enzyme in PGI~2~ synthesis), which indicates that the activation of eNOS--NO--cGMP pathway has a close relation to the protective effect of BA on ACh-induced EDR against oxidative stress.

Considerable evidences indicate that increased vascular oxidative stress plays an important role in endothelial dysfunction. \[[@ref22]\] Pyrogallol rapidly auto-oxidizes in oxygen-containing aqueous medium to generate O~2~^-^\[[@ref23]\] and has been used to induce vascular damage from ROS *in vitro*. In our study, preincubation with pyrogallol (500 μM) for 15 min markedly decreased EDR accompanying the increase of ROS production and the decrease of SOD activity in the isolated rat thoracic aortas, which is consistent with the previous studies and indicates that O~2~^-^ from the auto-oxidization of pyrogallol elevated enough oxidative stress to damage the endothelial function by disrupting the balance of ROS production and elimination. Excessive ROS alters the selective permeability of plasma membrane, represses the activity of cellular enzymes, and induces cell death through oxidative modifications of proteins, lipids, and DNA, \[[@ref24]\] all of which contribute to the weak EDR and hypertension induced by oxidative stress. In addition, the obviously decreased NO level and eNOS (the main cNOS in the rat aorta) activity in pyrogallol treated aortas may be partly responsible for the impairment of EDR in oxidative stress. Pretreatment with BA improved EDR in aortas exposure to pyrogallol derived O~2~^-^, which was abolished both by L-NAME and MB. We also found that BA reduced ROS production, reversed the decrease of NO level and eNOS activity induced by O~2~^-^. All these facts strengthen the above hypothesis and indicate that the antioxidative activity of BA helps to retain the bioavailability of endothelium derived NO and protects the aortic EDR against oxidative stress.

There are two main events involved in ROS quenching NO as the following. One is that O~2~^-^ rapidly reacts with NO to produce the strong oxidant ONOO^-^, which directly aggravates endothelial dysfunction. The other is that ONOO^-^ causes uncoupling of NOS by oxidizing the essential eNOS cofactor tetrahydrobiopterin, to produce ROS instead of NO. \[[@ref25]\] Therefore, oxidative stress is exacerbated and NO-related EDR is impaired. Activating the endogenous antioxidant enzymes might be effective in treating oxidative stress-induced endothelial dysfunction, which has been demonstrated by the previous study that SOD gene transfer improves intrahepatic endothelial function and reduces portal pressure,\[[@ref26]\] and again by our current results that BA improved the SOD activity, reduced ROS level, as well as ameliorated EDR in aorta subjected to exogenous O~2~^-^. Likewise, BA itself induced EDR concentration-dependently and enhanced eNOS-NO in normal aortas, which may also benefit EDR against oxidative stress.

In conclusion, we have shown that BA protected EDR in rat aortas against exogenous O~2~^-^, which may closely relate to the reduction of oxidative stress and activation of eNOS-NO pathway. Such endothelial protection conferred by BA may be pivotal to the beneficial effect of ZSS, in which the key active constituent is BA, in the cardiovascular system.
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